In the metastatic setting, programmed-death ligand-1 (PD-L1) status, high microsatellite instability (MSI-high), and high tumor mutational burden (TMB-high) further contribute to select patients who may benefit from immunotherapy. The gene discussed is CD274; the disease is neoplasm.